VEGFA and neoplasm: To further evaluate the feasibility of using the D5 promoter for in vivo tumor therapy, we constructed a therapeutic gene, RBDV-IgG1 Fc, that codes a fusion protein for amino acid residues 8–109 of VEGF-A and the Fc region of human IgG1.